APA (7th ed.) Citation

Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, & Chengwu Shen. (2024). Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, and Chengwu Shen. Cost-effectiveness Analysis of Camrelizumab Plus Paclitaxel and Carboplatin Versus Sintilimab Plus Gemcitabine and Cisplatin or Carboplatin for the First-line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Xiaoting Liu, et al. Cost-effectiveness Analysis of Camrelizumab Plus Paclitaxel and Carboplatin Versus Sintilimab Plus Gemcitabine and Cisplatin or Carboplatin for the First-line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland. Frontiers Media S.A., 2024.